Loading…
Arcus Biosciences, Inc. is projected to rise to $36.43 by 2027, a +26% move from its current price of $28.92. RCUS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $28.06 | $28.91 | $29.79 | -0.03% |
| Jul 13 | $27.71 | $28.90 | $30.15 | -0.05% |
| Jul 14 | $27.44 | $28.90 | $30.43 | -0.08% |
| Jul 15 | $27.21 | $28.89 | $30.67 | -0.11% |
| Jul 16 | $27.01 | $28.88 | $30.88 | -0.14% |
| Jul 17 | $26.83 | $28.87 | $31.07 | -0.16% |
| Jul 18 | $26.67 | $28.87 | $31.24 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.67 | $28.87 | $31.24 | -0.19% |
| Week 2 | $25.76 | $28.81 | $32.22 | -0.38% |
| Week 3 | $25.07 | $28.76 | $32.98 | -0.57% |
| Week 4 | $24.50 | $28.70 | $33.62 | -0.76% |
| Week 5 | $24.00 | $28.65 | $34.19 | -0.95% |
| Week 6 | $23.55 | $28.59 | $34.71 | -1.13% |
| Week 7 | $23.15 | $28.54 | $35.19 | -1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States. It operates within the Healthcare sector.
Its development portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trials for lung and gastrointestinal cancers. Zimberelimab is an anti-PD-1 antibody.
It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, in phase 3 and phase 1/1b trials for lung and pancreatic cancer. AB598, a CD39 antibody, is in Phase 1/1b for gastrointestinal cancer and AB801, an AXL inhibitor, is in Phase 1b for lung cancer. It has collaborations with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC.
BVF Partners L.P. supports discovery and development of compounds for inflammatory diseases; Bristol-Myers Squibb to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences was incorporated in 2015 and is based in Hayward, California.
Arcus Biosciences, Inc. (RCUS) is currently priced at $30.25 with a market capitalization of $3.8B and a rank of 1577. The stock shows a bullish near-term setup reflected in a bullish technical sentiment and an RSI of 70.
In the near term, the stock trades with the SMA50 at $24.73 and the SMA200 at $21.29, with a support level at $22.12 and a resistance level at $30.25. The 30-day trading range spans $24.16 to $37.87, indicating potential upside within that band.
Looking at the longer horizon, forecasts project a rising price path from 2026 onward, with the 2026 avg price at $30.25 and rising through 2027-2050. The year-by-year averages show substantial upside, including a 2030 avg of $85.34 and a 2050 avg of $627.02, with corresponding ROI figures that expand from 0% in 2026 to 1972.8% in 2050.
A major floor 36.3% below — a decisive break under it would weaken the trend.
The nearest floor, 23.5% below — buyers have tended to step in here.
The nearest ceiling, 7.5% above — a clean break opens room to run.
A major ceiling 25.6% above — clearing it would confirm fresh momentum.
Key RCUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.87 | Sell | $29.68 | Sell |
| MA 10 | $30.15 | Sell | $29.47 | Sell |
| MA 20 | $27.96 | Buy | $28.37 | Buy |
| MA 50 | $25.85 | Buy | $26.37 | Buy |
| MA 100 | $24.06 | Buy | $24.62 | Buy |
| MA 200 | $22.21 | Buy | $21.99 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.26 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 25.28 | Neutral |
| Williams %R (14) | -56.10 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 2.63 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 43.90 | Neutral |
| TRIX (15) | 0.83 | Buy |
| Awesome (5,34) | 3.54 | Buy |
| Ultimate (7,14,28) | 46.19 | Neutral |
| Momentum (10) | -1.33 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 29.76 | Sell |
| ADX (14) | 23.26 | Buy |
| ATR (14) | 0.73 | Info |
The 30-day technical picture is bullish, supported by a bullish sentiment and an RSI of 70. The stock trades near resistance at $30.25, with the 50-day moving average at $24.73 and the 200-day moving average at $21.29.
Over the last 30 days, the price has traded within a range of $24.16 to $37.87, signaling a capability for upside while holding above key support around $22.12.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.85 | $28.92 | $37.18 | 0% | Neutral | |
| $28.74 | $36.43 | $49.00 | +26% | Bullish | |
| $32.94 | $43.05 | $60.27 | +49% | Bullish | |
| $41.56 | $55.74 | $80.50 | +93% | Bullish | |
| $50.82 | $69.73 | $103.37 | +141% | Bullish | |
| $56.08 | $78.55 | $119.14 | +172% | Bullish | |
| $59.81 | $85.42 | $132.23 | +195% | Bullish | |
| $61.19 | $88.98 | $140.32 | +208% | Bullish | |
| $68.24 | $100.97 | $161.95 | +249% | Bullish | |
| $78.86 | $118.64 | $193.30 | +310% | Bullish | |
| $123.57 | $200.53 | $348.95 | +593% | Bullish | |
| $239.23 | $443.03 | $848.09 | +14.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.85 | $28.92 | $35.14 | +0.00% |
| August 2026 | $24.33 | $28.80 | $35.06 | -0.43% |
| September 2026 | $23.65 | $28.21 | $34.76 | -2.03% |
| October 2026 | $24.27 | $29.13 | $36.26 | +3.27% |
| November 2026 | $24.70 | $29.82 | $37.43 | +2.35% |
| December 2026 | $24.21 | $29.39 | $37.18 | -1.45% |
Click any year to see its month-by-month RCUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Arcus Biosciences, Inc.'s 2026 outlook centres on $28.92, within a $18.85 to $37.18 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, RCUS could reach as high as $49.00, with a base case around $36.43 and support toward $28.74 — roughly +26% from $28.92. Buyers look set to stay in control over this stretch.
Expect RCUS to range from $32.94 to $60.27 through 2028. The $43.05 average target implies a +49% move from current prices. That is up +18% on the projected 2027 average. Momentum favours further upside here.
The RCUS price prediction for 2029 points to an average of $55.74 (low $41.56, high $80.50) — a potential gain of +93% on today's $28.92. Buyers look set to stay in control over this stretch.
In 2030, RCUS is projected to trade between $50.82 and $103.37, averaging $69.73 — a potential gain of +141% from today's $28.92. That is up +25% on the projected 2029 average. Momentum favours further upside here.
Arcus Biosciences, Inc.'s 2031 outlook centres on $78.55, within a $56.08 to $119.14 range. That is up +13% on the projected 2030 average. That marks a +172% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, RCUS could reach as high as $132.23, with a base case around $85.42 and support toward $59.81 — roughly +195% from $28.92. Momentum favours further upside here.
Expect RCUS to range from $61.19 to $140.32 through 2033. The $88.98 average target implies a +208% move from current prices. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The RCUS price prediction for 2034 points to an average of $100.97 (low $68.24, high $161.95) — a potential gain of +249% on today's $28.92. Momentum favours further upside here.
In 2035, RCUS is projected to trade between $78.86 and $193.30, averaging $118.64 — a potential gain of +310% from today's $28.92. That is up +17% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Arcus Biosciences, Inc.'s 2040 outlook centres on $200.53, within a $123.57 to $348.95 range. That is up +69% on the projected 2035 average. That marks a +593% change versus current levels. Momentum favours further upside here.
By 2050, RCUS could reach as high as $848.09, with a base case around $443.03 and support toward $239.23 — roughly +14.3x from $28.92. Buyers look set to stay in control over this stretch.
Investing $1,000 in RCUS today (≈ 34.578147 RCUS) could be worth
$15,319.14
+$14,319.14 (+1432%) by 2050 · US Dollar
Based on the average projected RCUS price of $443.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCUSwould be worth at today's price.
$1,000 invested in RCUS on Jul 10, 2025 (≈ 104.821803 RCUS) would be worth
$3,031.45
+$2,031.45 (+203.1%) today · 3.03× · US Dollar
Based on a RCUS entry price of $9.54 vs. today's $28.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $30.33 | $953.51 | -4.6% |
| 1 month ago | $22.12 | $1,307.41 | +30.7% |
| 3 months ago | $22.34 | $1,294.54 | +29.5% |
| 6 months ago | $21.3 | $1,357.75 | +35.8% |
| 1 year ago | $9.54 | $3,031.45 | +203.1% |
| All time (5.0y) ago | $29.33 | $986.02 | -1.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCUS forecast.
Our base-case forecast reaches $58.00 around 2030.
Implied market cap at $58.00: $7.29B
The multi-year forecast points to a strong uptrend with meaningful upside through 2030 and beyond. The 2030 average price is $85.34, with a 182.1% ROI, and bullish sentiment. By 2040 the average price rises to $257.70 with a 751.9% ROI, remaining bullish.
By 2050, the average price is projected to $627.02 with a 1972.8% ROI, continuing a bullish stance, though these are estimates and not guarantees.
The forecast shows continued upside across a long horizon, but investors should consider that outcomes depend on market conditions and company progress, and actual results may differ from projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $85.34, a low of $60.46, a high of $130.50, a ROI of 182.1%, and a bullish sentiment.
The forecast charts a rising path with bullish sentiment from 2027 onward; 2027 avg $40.72 (ROI 34.6%), 2028 avg $48.70 (ROI 61%), 2029 avg $65.39 (ROI 116.2%), 2030 avg $85.34 (ROI 182.1%), culminating in 2050 avg $627.02 (ROI 1972.8%). These are estimates, not guarantees.
Yes. The 2030 maximum in the forecast is $130.50.
Current price is $30.25 and market capitalization is $3.8B.
The near-term setup is bullish with RSI(14) at 70. The stock trades with a resistance at $30.25 and a support at $22.12; SMA50 is $24.73 and SMA200 is $21.29; the 30-day range runs from $24.16 to $37.87.
Arcus Biosciences, Inc. Community Discussion
0Share your Arcus Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.